💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Ritter Pharma's lead candidate shows encouraging action in mid-stage lactose intolerance study; shares ahead 6%

Published 03/12/2018, 03:06 PM
© Reuters.  Ritter Pharma's lead candidate shows encouraging action in mid-stage lactose intolerance study; shares ahead 6%
QLGN
-
  • Nano cap Ritter Pharmaceuticals (RTTR +6.2%) is up on more than a 4x surge in volume on the heels of its announcement of positive data from a Phase 2b clinical trial assessing lead drug RP-G28 in 377 patients intolerant of lactose.
  • After 30 days' treatment with RP-G28, patients experienced a significant increase in lactic acid bacteria in the gut, implying that they would be better able to digest lactose.
  • A Phase 3 study should launch next quarter.
  • RP-G28, a highly purified galactooligosaccharide, is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. If approved, it will be the first drug cleared by the FDA for the indication.
  • Previously: Ritter solidifies Phase 3 program for RP-G28; shares up 6% (Aug. 18, 2017)
  • Now read: Regeneron Pharmaceuticals (REGN) Results Of ODYSSEY OUTCOMES Trial - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.